Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amprenavir Dual vs Single PI Regimens in HIV Salvage
NCT00000912Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of amprenavir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of subjects with plasma HIV-1 RNA <= 200 copies/ml at 24 weeks. Status: completed.
02
Drugs
amprenavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000912.